CRO & CDMOFrom development to commercial realityHelping biopharmaceutical innovators build scalable, manufacturable, and commercially viable processes from the start. more ➔
autoimmune diseaseAATec is pioneering a new approach to lung diseasesAATec is advancing ATL-105, a new recombinant version of alpha-1 antitrypsin for inhalation, into clinical development for chronic respiratory diseases. Rüdiger Jankowsky, CEO, and Gabriele Matschiner, … more ➔
BiosimilarsPerfusion for next generation biosimilarsPerfusion is here, and it is rewriting the rules of biologics and biosimilar manufacturing. What was once experimental has become industrial reality: scalable, robust, regulatorily accepted, and commercially … more ➔
CRO & CDMOEvery process is different. Not the platform.For CDMOs, flexible upstream platforms can help streamline process development while maintaining reproducibility and continuity across scales. more ➔
CRO & CDMODesigning biologics for commercial successJustyna Adamczyk, Associate VP Integrated MS&T at Rezon Bio, discusses why integrating development and manufacturing strategies is key to improving late-stage efficiency and commercialization readin … more ➔
New England BiolabsThe Bridge to your successCustomized Enzymes and Reagents from New England Biolabs. Creating the right partnership is essential when pioneering a new life science product. more ➔
Cell & Gene TherapyEurope’s CGT advantage at riskIndustry leaders at Advanced Therapies Europe 2026 warned that Europe must tackle barriers across commercialisation, regulation, reimbursement, manufacturing and patient access to retain its global … more ➔
intellectual propertyG 1/25: Form over function and how expensive is it?In proceedings before the European Patent Office (EPO), applicants are required to „adapt“ the description to the claims of a patent application once the claims are deemed allowable. The adaptation … more ➔
SLASCall for PapersSLAS Journals Spotlight AI in Drug DiscoveryAs artificial intelligence reshapes life sciences research, two leading Elsevier Gold Open Access peer-reviewed journals, SLAS Discovery and SLAS Technology, invite contributions to Special Issues exploring … more ➔
Commercial Strategy3PBIOVIAN appoints Ponchi Kantt-Neaz as Global Executive Business DirectorThe appointment of Ponchi marking an important milestone in the company’s global commercial strategy and further strengthening its commercial leadership as the company continues to expand its presence … more ➔
SLAS